Grand Challenges Annual Meeting to Include MB Presentation

Oxafence to be featured in a poster series at the upcoming Grand Challenges Annual Meeting taking place October 8-11 in Dakar, Senegal. The theme for the Annual Meeting is "Science Saves Lives."

The Annual Meeting, which is supported by the Bill & Melinda Gates Foundation and its Grand Challenges Partners, has become a preeminent forum for global health Research & Development. It convenes researchers and practitioners and provides a platform to learn about scientific advances, and build collaborations.

The poster presentation, authored by Dr. May Chu, Ph. D., Clinical Professor at the Colorado School of Public Health Department of Epidemiology and Interim Director of the Center for Global Health and Singletto’s Drs. Tom Lendvay, James Chen, and Christopher Mores, highlights the peer-reviewed and published Development of Methods for Mask and N95 Decontamination (DeMaND) study, as well as follow-on DeMaND2 and Singletto-sponsored studies. 

Dr. May Chu led the DeMaND study efforts and is a proponent of the antimicrobial Photodynamic Inactivation (aPDI) method using Methylene Blue (MB) for pathogen inactivation applications.  Drs. Lendvay, Chen, and Mores, who lead Singletto’s R&D, were co-authors with Chu on the original DeMaND study and also authored several follow-on DeMaND2 studies.

For more information on the Grand Challenges Annual Meeting, visit https://www.grandchallenges.org/annual-meeting.

The DeMaND study was published in the Infection Control and Hospital Epidemiology medical journal (2021) and follow-on DeMaND2 studies were published in the American Journal of Infection Control (2022). Open Philanthropy partially funded the DeMaND study. The DeMaND2 study was supported by the World Health Organization through the German Federal Ministry of Health (BMG) grant.